According to a new report, published by KBV research, The Global Thrombosis And Hemostasis Biomarkers Market size is expected to reach $7.4 billion by 2030, rising at a market growth of 5.6% CAGR during the forecast period.
The Analyzers segment is showcasing a CAGR of 6.3% during (2023 - 2030). The majority of automated analyzers used in hemostasis and thrombosis labs nowadays are also able to do other tests, including chromogenic, latex agglutination, as well as enzymatic immunoassays. Additionally, novel analyzers that more precisely evaluate the function of platelets in human illnesses, such as stroke, cancer, ischemic heart disease (ISD), sickle cell disease, and others, have been developed.
The Deep Vein Thrombosis (DVT) segment is leading the Global Thrombosis And Hemostasis Biomarkers Market by Application in 2022 thereby, achieving a market value of $3.1 billion by 2030. The deep veins of the lower leg, thigh, pelvis, and arm are the most prevalent sites for blood clots to form in deep vein thrombosis, a dangerous and underdiagnosed condition. 1-2 instances per 1,000 people are thought to occur in DVT each year. However, certain people continue to be at a higher risk than others. It affects people of various ages, genders, and nationalities.
The Hospitals & Clinics segment has shown the growth rate of 5.8% during (2023 - 2030). The demand for hospitals with better diagnostic services has increased as a result of ongoing transformations in the healthcare sector. The category growth has been greatly aided by the rise in healthcare spending around the world. Regulatory authorities frequently work in conjunction with hospitals to monitor disease frequency as they gather and manage data. With the healthcare industry's continual changes, there is a greater requirement for hospitals with cutting-edge equipment.
The Clinical Laboratory Tests segment is leading the Global Thrombosis And Hemostasis Biomarkers Market by Location in 2022 thereby, achieving a market value of $5 billion by 2030. Clinical laboratory tests are used to evaluate the severity of the illness, uncover anomalies in the process of blood clotting, and inform therapy choices. Moreover, the development of the clinical laboratory testing business is also being fueled by the rising investment in healthcare facilities, particularly in emerging nations.
The D-Dimer segment is poised to grow at a CAGR of 6% during (2023 - 2030). Medical experts used to do increased d-dimer testing by drawing blood samples with needles and submitting them for additional analysis to detect the presence of dangerous blood clots. The test makes use of monoclonal antibodies (mAb) of latex particles mixed with increased d-dimer, which raises the molecular mass of the immunocomplexes of the test sample. Both turbidimetric analyzers and photometrical analyzers look at the variations in turbidity of the specimen.
The North America market dominated the Global Thrombosis And Hemostasis Biomarkers Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $2.5 billion by 2030. The Europe market is exhibiting a CAGR of 5.4% during (2023 - 2030). Additionally, The Asia Pacific market would showcase a CAGR of 6.5% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/thrombosis-and-hemostasis-biomarkers-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers AG (Siemens AG), Abbott Laboratories, BioMérieux S.A., Horiba Ltd., QuidelOrtho Corporation, Werfen, S.A., Diazyme Laboratories, Inc. (General Atomics) and BioMedica Diagnostics Inc. (Scotia Investments Family of Companies).
By Product
By Application
By End-Use
By Location
By Type
By Geography
Companies Profiled
Unique Offerings 
